What is Teriparatide (PTH 1-34)?
Teriparatide is a synthetic 34-amino-acid peptide. It corresponds to the N-terminal fragment of parathyroid hormone (PTH). It is a parathyroid hormone receptor 1 (PTH1R) agonist and is supplied by BehemothLabz as a research-grade peptide. It is available for:
- In vitro receptor binding investigation
- Preclinical bone remodeling pathway research, and
- Osteoblast biology laboratory studies
Important clarification: A pharmaceutical formulation of teriparatide is FDA-approved by prescription for specific clinical indications under medical supervision. However, the research-grade teriparatide supplied here is a distinct laboratory preparation. It is a 10mg lyophilized peptide vial produced for preclinical and in vitro research use only. It is not a pharmaceutical product, not a clinical preparation, and is not supplied for any human application. It is not a dietary supplement.
Disclaimer: Teriparatide (PTH 1-34) is a research compound supplied for laboratory use only. It is not approved by the FDA for human or veterinary use in this form. It is not intended to diagnose, treat, cure, or prevent any disease. This product is strictly for laboratory research purposes only.
ATTENTION: This product is strictly for LABORATORY AND RESEARCH PURPOSES ONLY. Not for human or veterinary use.
Mechanism of Action of Teriparatide (PTH 1-34)
PTH1R Receptor Binding and cAMP Signaling Research:
Teriparatide has been investigated in preclinical cell and tissue models as a PTH1R agonist. In isolated receptor preparations and cell culture systems, PTH1R binding by teriparatide has been observed to activate adenylate cyclase, increasing intracellular cAMP levels and activating downstream protein kinase A signaling cascades. This receptor-mediated second messenger pathway is the primary mechanism under investigation in PTH1R pharmacology research.
Osteoblast Activation and Bone Formation Pathway Research:
Research in this area has investigated how PTH1R signaling may shift the balance between bone-forming and bone-resorbing cellular activity in experimental model systems.
RANKL/OPG Pathway Modulation Research:
In animal model studies, teriparatide has been investigated for its potential to modulate RANKL (receptor activator of nuclear factor kappa-B ligand) and osteoprotegerin (OPG) signaling. The interaction between PTH1R activation and the RANKL/OPG axis in bone remodeling model systems remains an active area of preclinical investigation.
Bone Remodeling Marker Research:
In preclinical bone remodeling model systems, teriparatide administration has been observed to modulate serum markers of bone formation and resorption, including osteocalcin and CTX-1, in a dose and frequency-dependent manner. This has made it a reference compound in preclinical studies investigating bone remodeling dynamics.
Chemical Properties of Teriparatide (PTH 1-34)
| Property | Detail |
| Molecular Formula | C₁₈₁H₂₉₁N₅₅O₅₁S₂ |
| Molecular Weight | 4,117.72 g/mol |
| CAS Number | 52232-67-4 |
| PubChem CID | 16133850 |
| Peptide Length | 34 amino acids |
| Physical Form | White to off-white lyophilized powder |
| Purity | ≥98% (HPLC verified, per batch COA) |
| Solubility | Sterile water or acetic acid solution |
| Storage | −20°C, protected from light and moisture |
| Synonyms | PTH 1-34, Parathyroid Hormone Fragment 1-34, hPTH(1-34) |
| Classification | Research Use Only (RUO) |
Formulation note: The acetate salt form (CAS 99294-94-7, MW 4,177.83 g/mol) is also available from some suppliers. The values above reflect the free peptide entry for CAS 52232-67-4. Each BehemothLabz batch comes with a Certificate of Analysis confirming the specific molecular identity and form of the shipped material.
Research Applications
- PTH1R receptor binding kinetics and structure-activity relationship studies
- Osteoblast differentiation and apoptosis pathway investigation in primary cell culture
- RANKL/OPG signaling axis research in preclinical bone remodeling model systems
- Comparative PTH fragment pharmacology studies against full-length PTH(1-84) analogs
- Bone formation and resorption marker modulation studies (in rodent preclinical models)
- cAMP second messenger signaling research in PTH1R-transfected cell line systems
Risk & Handling
Teriparatide is a synthetic polypeptide PTH1R agonist under investigation in preclinical bone remodeling research.
Risk tier: HIGH.
This rating reflects teriparatide’s potent endocrine activity on calcium homeostasis pathways, the bioactive concentrations used in preclinical research, and the need for strict handling protocols to prevent accidental exposure during reconstitution.
Researchers must observe:
- Handling Precautions: Teriparatide should be handled exclusively in a controlled laboratory environment by trained personnel. Avoid skin and eye contact during reconstitution and handling. Use appropriate PPE at all times.
- Exposure Risks: Teriparatide is a PTH1R agonist research peptide that is thought to modulate calcium homeostasis, cAMP signaling, and bone remodeling pathways in preclinical models. No human safety data has been established for the research-grade formulation supplied here.
- Storage: Store lyophilized teriparatide at −20°C in a dry, dark environment. Protect from light, heat, and moisture at all times. Avoid repeated freeze-thaw cycles.
Why Choose BehemothLabz to Buy Teriparatide (PTH 1-34)?
BehemothLabz supplies research-grade teriparatide with batch-specific Certificates of Analysis confirming molecular identity and purity against CAS 52232-67-4 reference data. Every batch is independently tested by a third-party laboratory. BehemothLabz does not self-certify.
Batch-specific identity confirmation becomes a key parameter for reproducible experimental design when a product like teriparatide is commercially available in both free peptide and acetate salt forms. Each lot is characterized by HPLC retention time and mass spectrometry to confirm the specific form of the shipped material.
BehemothLabz Disclaimer
ATTENTION: All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.
Please make sure you go through the Terms and Conditions and familiarize yourself with them, as it is important. Kindly research the scientific uses of this product before making any purchases. Make note that the packaging and labels of the product may differ from those shown on the website.
Buying the product means you agree to our Terms and Conditions. You can contact our customer service team at support@behemothlabz.com if you are not fully satisfied with the product.
Teriparatide (PTH 1-34) Research FAQs
What is Teriparatide (PTH 1-34)?
Teriparatide is a synthetic 34-amino acid peptide. It corresponds to the N-terminal fragment of parathyroid hormone. So, it acts as a PTH1R agonist.
How does Teriparatide interact with PTH1R in experimental settings?
Teriparatide binds to the PTH1R receptor and activates adenylate cyclase. This raises intracellular cAMP and triggers PKA signaling downstream.
What is the difference between research-grade and pharmaceutical teriparatide?
A pharmaceutical formulation of teriparatide is FDA-approved for specific clinical indications. The research-grade teriparatide supplied by BehemothLabz is a distinct laboratory preparation. It is a 10mg lyophilized peptide vial produced for preclinical and in vitro research use only.
What is the purity of BehemothLabz Teriparatide?
Behemoth Labz tests every batch through independent third-party laboratories. Each listing includes a public COA with purity and concentration data confirmed at ≥98% by HPLC. External labs verify every lot.
Is Teriparatide (PTH 1-34) safe for human use?
No. The research-grade teriparatide supplied here is not approved by the FDA for human or veterinary use. No regulatory body has cleared this laboratory formulation for any health application. BehemothLabz sells it for laboratory research only.
How should Teriparatide (PTH 1-34) be stored?
Store at −20°C in a dry, dark environment, away from light, heat, and moisture. Avoid repeated freeze-thaw cycles. Always refer to the batch COA for specific guidance. For storage questions, contact support@behemothlabz.com
References
- Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007;40(6):1434–1446. https://pubmed.ncbi.nlm.nih.gov/17517365/
- Jilka RL, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. Journal of Clinical Investigation. 1999;104(4):439–446. https://pubmed.ncbi.nlm.nih.gov/10449436/
ATTENTION: All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.
